💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tebentafusp

CHEMBL4297990 Phase 4 承認済み Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Tebentafusp is a first-in-class immune mobilizing monoclonal T-cell receptor against cancer (ImmTAC) that targets gp100, a melanocyte lineage antigen presented by HLA-A*02:01, and simultaneously engages CD3 on T cells to redirect cytotoxic killing toward uveal melanoma cells. It is the first approved therapy specifically for HLA-A*02:01-positive uveal melanoma, a disease with historically very poor prognosis. Its T-cell receptor-based targeting mechanism allows recognition of intracellular antigens presented on the cell surface via MHC, an approach not accessible to conventional antibodies.

治療領域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Melanoma Breast Cancer Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Tebentafusp is a first-in-class immune mobilizing monoclonal T-cell receptor against cancer (ImmTAC) that targets gp100, a melanocyte lineage antigen presented by HLA-A*02:01, and simultaneously engages CD3 on T cells to redirect cytotoxic killing toward uveal melanoma cells. It is the first approved therapy specifically for HLA-A*02:01-positive uveal melanoma, a disease with historically very poor prognosis. Its T-cell receptor-based targeting mechanism allows recognition of intracellular antigens presented on the cell surface via MHC, an approach not accessible to conventional antibodies.

Yes, Tebentafusp is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297990. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.